Chronic myeloid leukemia: "Archetype" of the impact of targeted therapies;Leucémie myéloïde chronique: « archétype » de l'impact des traitements ciblés

Pathologie Biologie

Volumn 60, Issue 4, 2012, Pages 239-245

  Nasr, R ^a   Bazarbachi, A ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

BCR ABL; Chronic myeloid leukemia; Imatinib; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

IMATINIB;

ARTICLE; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; HEALTH CARE SYSTEM; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; MOLECULARLY TARGETED THERAPY;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR TARGETED THERAPY; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TRANSLOCATION, GENETIC;

EID: 84864744865     PISSN: 03698114     EISSN: 17683114     Source Type: Journal    
DOI: 10.1016/j.patbio.2012.05.010     Document Type: Article

References (69)

1. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., Kantarjian H.M. The biology of chronic myeloid leukemia. N Engl J Med 1999, 341(3):164-172.
2. Radich J.P. The biology of CML blast crisis. Hematology 2007, 1:384-391.
3. Bennett J.H. Case of hypertrophy of the spleen and liver in which death took place from suppuration of the blood. Edinb Med Surg 1845, J64:413-423.
4. Virchow R. Weisses blut. Frorieps Notizen 1845, 36:151-156.
5. Neumann E. Ein Fall Von Leukämie Mit Erkrankung Des Knochenmarks. Archive der Heilkunde 1870.
6. Nowell P., Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science 1960, 32:1497.
7. Rowley J.D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293.
8. Fialkow P.J., Jacobson R.J., Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977, 63(1):125-130.
9. Groffen J., Stephenson J.R., Heisterkamp N., de Klein A., Bartram C.R., Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984, 36:93-99.
10. Abelson H.T., Rabstein L.S. Lymphosarcoma: virus-induced thymic-independent disease in mice. Cancer Res 1970, 30:2213-2222.
11. Bartram C.R., de Klein A., Hagemeijer A., van Agthoven T., Geurts van Kessel A., Bootsma D., et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983, 306:277-280.
12. Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247:1079-1082.
13. Goldman J.M., Melo J.V. Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med 2003, 349(15):1451-1564.
14. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990, 247:824-830.
15. Heisterkamp N., Jenster G., ten Hoeve J., Zovich D., Pattengale P.K., Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature 1990, 344:251-253.
16. Groffen J., Voncken J.W., Kaartinen V., Morris C., Heisterkamp N. Ph-positive leukemia: a transgenic mouse model. Leuk Lymphoma 1993, 11(Suppl. 1):19-24.
17. Forkner C.E. Leukemia and allied disorders 1938, Macmillan, New York, p. 126-35.
18. Puccetti E., Güller S., Orleth A., Brüggenolte N., Hoelzer D., et al. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Res 2000, 60:3409-3413.
19. Ito K., Bernardi R., Morotti A., Matsuoka S., Saglio G., Ikeda Y., et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008, 453(7198):1072-1078.
20. Galton D.A. Myleran in chronic myeloid leukaemia; results of treatment. Lancet 1953, 264:208-213.
21. Savage D.G., Goldman J.M. Allografting for chronic myeloid leukemia. Curr Opin Hematol 1997, 4:369-376.
22. Hansen J.A., Gooley T.A., Martin P.J., Appelbaum F., Chauncey T.R., Clift R.A., et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998, 338:962-968.
23. Talpaz M., Kantarjian H., Kurzrock R., Trujillo J.M., Gutterman J.U. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 1991, 114:532-538.
24. Hehlmann R., Heimpel H., Hasford J., Kolb H.J., Pralle H., Hossfeld D.K., et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994, 84:4064-4077.
25. Guilhot F., Chastang C., Michallet M., Guerci A., Harousseau J.L., Maloisel F., et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997, 337:223-229.
26. Bonifazi F., de Vivo A., Rosti G., Guilhot F., Guilhot J., Trabacchi E., et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001, 98:3074-3081.
27. Talpaz M., McCredie K., Kantarjian H., Trujillo J., Keating M., Gutterman J. Chronic myelogenous leukaemia: haematological remissions with alpha interferon. Br J Haematol 1986, 64(1):87-95.
28. Anafi M., Gazit A., Zehavi A., Ben Neriah Y., Levitzki A. Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood 1993, 82:3524-3529.
29. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
30. Deininger M., Goldman J.M., Lydon N.B., Melo J.V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood 1997, 90:3691-3698.
31. Gambacorti-Passerini C., le Coutre P., Mologni L., Fanelli M., Bertazzoli C., Marchesi E., et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997, 23:380-394.
32. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037.
33. Kantarjian H., Charles Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645-652.
34. O'Brien S.G.M.D., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
35. Hughes T.P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M.L., et al. International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349(15):1423-1432.
36. Hahn E.A., Glendenning G.A., Sorensen M.V., Hudgens S.A., Druker B.J., Guilhot F., et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 2003, 21(11):2138-2146.
37. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355(23):2408-2417.
38. Deininger M.W. Milestones and monitoring in patients with CML treated with imatinib. Hematology Am Soc Hematol Educ Program 2008, 1:419-426.
39. Sawyers C.L., Hochhaus A., Feldman E., Goldman J.M., Miller C.B., Ottmann O.G., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99(10):3530-3539.
40. Talpaz M., Silver R.T., Druker B.J., Goldman J.M., Gambacorti-Passerini C., Guilhot F., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002, 99(6):1928-1937.
41. Preudhomme C., Guilhot J., Nicolini F.E., Guerci-Bresler A., Rigal-Huguet F., Maloisel F., et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010, 363(26):2511-2521.
42. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354(24):2531-2541.
43. Ramirez P., DiPersio J.F. Therapy options in imatinib failures. Oncologist 2008, 13(4):424-434.
44. Saglio G., Kim D.W., Issaragrisil S., le Coutre P., Etienne G., Lobo C., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362(24):2251-2259.
45. Cortes J.E., Jones D., O'Brien S., Jabbour E., Konopleva M., Ferrajoli A., et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010, 28(3):392-397.
46. Kantarjian H., Shah N.P., Hochhaus A., Cortes J., Shah S., Ayala M., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362(24):2260-2270.
47. Keller G., Schafhausen P., Brummendorf T.H. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia. Expert Rev Hematol 2009, 2(5):489-497.
48. O'Hare T., Shakespeare W.C., Zhu X., Eide C.A., Rivera V.M., Wang F., et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16(5):401-412.
49. Huang W.S., Metcalf C.A., Sundaramoorthi R., Wang Y., Zou D., Thomas R.M., et al. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methyliperazin-1-yl)methyl]-3 (trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 2010, 53(12):4701-4719.
50. Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27(35):6041-6051.
51. Mahon F.X., Deininger M.W., Schultheis B., Chabrol J., Reiffers J., Goldman J.M., et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000, 96(3):1070-1079.
52. Branford S., Rudzki Z., Walsh S., Grigg A., Arthur C., Taylor K., et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002, 99(9):3472-3475.
53. Mahon F.X., Belloc F., Lagarde V., Chollet C., Moreau-Gaudry F., Reiffers J., et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003, 101(6):2368-2373.
54. Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101(2):690-698.
55. Kantarjian H., Pasquini R., Levy V., Jootar S., Holowiecki J., Hamerschlak N., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009, 115(18):4136-4147.
56. Barthe C., Cony-Makhoul P., Melo J.V., Mahon J.R. Roots of clinical resistance to STI-571 cancer therapy. Science 2001, 293(5538):2163.
57. Branford S., Rudzki Z., Walsh S., Parkinson I., Grigg A., Szer J., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003, 102(1):276-283.
58. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2(2):117-125.
59. Nicolini F.E., Basak G.W., Soverini S., Martinelli G., Mauro M.J., Muller M.C., et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 2011, 118:5697-5700.
60. Quintas-Cardama A., Kantarjian H., Cortes J. Third-generation tyrosine kinase inhibitors and beyond. Semin Hematol 2010, 47(4):371-380.
61. Pye S.M., Cortes J., Ault P., Hatfield A., Kantarjian H., Pilot R., et al. The effects of imatinib on pregnancy outcome. Blood 2008, 111(12):5505-5508.
62. Schultheis B., Nijmeijer B.A., Yin H., Gosden R.G., Melo J.V. Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. Leuk Res 2012, 36:271-274.
63. Leguay T, Mahon FX. Leucémie myéloïde chronique. Hématologie 2005;13-011-B-10.
64. Jabbour E., Cortes J., Kantarjian H. Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?. Oncology (Williston Park) 2007, 21(6):653-662. [discussion 663-4; 667-8].
65. Frame D. New strategies in controlling drug resistance. J Manag Care Pharm 2007, 13(8 Suppl. A):13-17.
66. Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., Baxter E.J., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002, 347:481-487.
67. Gleich G.J., Leiferman K.M., Pardanani A., Tefferi A., Butterfield J.H. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002, 359:1577-2158.
68. Joensuu H., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344:1052-1056.
69. Van Oosterom A.T., Judson I., Verweij J., Stroobants S., Donato di Paola E., Dimitrijevic S., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001, 358:1421-1423.